The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Centene beat expectations on revenue and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue improved significantly and GAAP earnings per share expanded.
Margins dropped across the board.
Centene booked revenue of $1.51 billion. The 14 analysts polled by S&P Capital IQ predicted revenue of $1.43 billion on the same basis. GAAP reported sales were 28% higher than the prior-year quarter's $1.18 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.57. The 17 earnings estimates compiled by S&P Capital IQ predicted $0.55 per share. GAAP EPS of $0.57 for Q4 were 14% higher than the prior-year quarter's $0.50 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 18.4%, 370 basis points worse than the prior-year quarter. Operating margin was 3.4%, 70 basis points worse than the prior-year quarter. Net margin was 2.0%, 10 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $1.67 billion. On the bottom line, the average EPS estimate is $0.48.
Next year's average estimate for revenue is $7.53 billion. The average EPS estimate is $2.72.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Centene is outperform, with an average price target of $41.63.
If you're interested in health care stocks like Centene, you might want to expand your horizons to find maximum returns. Follow the money and meet a prime candidate for major returns in our new report: "Discover the Next Rule-Breaking Multibagger." Click here for instant access to this free report.
- Add Centene to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
The Insurer That's Crushing It in Obamacare
Other insurers may be retreating from the Affordable Care Act marketplaces, but this insurer's not only making money on the exchanges -- it's also planning to sell plans in more states next year.
What Managed Care Organizations Are, and How Investors Can Profit From Them
Find out more about the way that most Americans get their healthcare.
Buy This Insurer Instead of Molina Health
New management may breathe new life into Molina Health's finances, but competitor Centene Corp. could be the better stock to buy.